These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37153287)

  • 1. Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?
    RoyChaudhuri S; Majumder A; Sanyal D; Chakraborty S; Chuyan S
    Cureus; 2023 Apr; 15(4):e37065. PubMed ID: 37153287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India.
    RoyChaudhuri S; Majumder A; Mukherjee P; Sanyal D; Chakraborty S; Chuyan S
    Cureus; 2023 Jun; 15(6):e40179. PubMed ID: 37431351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.
    Al Hayek AA; Al Dawish MA
    Adv Ther; 2022 Apr; 39(4):1582-1595. PubMed ID: 35119622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings.
    Yamada H; Yoshida M; Funazaki S; Morimoto J; Tonezawa S; Takahashi A; Nagashima S; Masahiko K; Kiyoshi O; Hara K
    J Cardiovasc Dev Dis; 2023 Apr; 10(4):. PubMed ID: 37103055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.
    Swift C; Frazer MS; Gronroos NN; Sargent A; Leszko M; Buysman E; Alvarez S; Dunn TJ; Noone J; Guevarra M
    Diabetes Ther; 2024 Jul; 15(7):1547-1559. PubMed ID: 38722496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 7. Benefits of a Switch from Intermittently Scanned Continuous Glucose Monitoring (isCGM) to Real-Time (rt) CGM in Diabetes Type 1 Suboptimal Controlled Patients in Real-Life: A One-Year Prospective Study
    Préau Y; Galie S; Schaepelynck P; Armand M; Raccah D
    Sensors (Basel); 2021 Sep; 21(18):. PubMed ID: 34577338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.
    Marques Vidas M; López-Sánchez P; Sánchez-Briales P; López Illazquez MV; Portolés J
    J Clin Med; 2024 Aug; 13(17):. PubMed ID: 39274378
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The appropriate cut-off point of time in range (TIR) for evaluating glucose control in type 2 diabetes mellitus].
    Dai DJ; Lu JY; Zhang L; Shen Y; Mo YF; Lu W; Zhu W; Bao YQ; Zhou J
    Zhonghua Yi Xue Za Zhi; 2020 Oct; 100(38):2990-2996. PubMed ID: 33086449
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 13. Glucose Regulation Beyond HbA
    den Braber N; Vollenbroek-Hutten MMR; Westerik KM; Bakker SJL; Navis G; van Beijnum BF; Laverman GD
    Diabetes Care; 2021 Jul; 44(10):2238-44. PubMed ID: 34301732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
    Powell J; Piszczatoski C; Taylor JR
    Clin Ther; 2020 Oct; 42(10):2100-2116. PubMed ID: 32873415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus.
    Kurozumi A; Okada Y; Mita T; Wakasugi S; Katakami N; Yoshii H; Kanda K; Nishida K; Mine S; Tanaka Y; Gosho M; Shimomura I; Watada H
    Diabetes Res Clin Pract; 2022 Apr; 186():109836. PubMed ID: 35314256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.
    Aroda VR; Faurby M; Lophaven S; Noone J; Wolden ML; Lingvay I
    Diabetes Obes Metab; 2021 Sep; 23(9):2177-2182. PubMed ID: 34060209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.
    Keyu G; Jiaqi L; Liyin Z; Jianan Y; Li F; Zhiyi D; Qin Z; Xia L; Lin Y; Zhiguang Z
    Front Public Health; 2022; 10():990281. PubMed ID: 36091534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualization of recommendations from the international consensus on continuous glucose monitoring-derived metrics in Japanese children and adolescents with type 1 diabetes.
    Urakami T; Yoshida K; Kuwabara R; Mine Y; Aoki M; Suzuki J; Morioka I
    Endocr J; 2020 Oct; 67(10):1055-1062. PubMed ID: 32565500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.
    Joshi SR; Rajput R; Chowdhury S; Singh AK; Bantwal G; Das AK; Unnikrishnan AG; Saboo BD; Kesavadev J; Ghosal S; Mohan V
    Diabetes Metab Syndr; 2022 Jun; 16(6):102508. PubMed ID: 35653929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.